Neurocrine Biosciences (NBIX) to Release Quarterly Earnings on Tuesday
Neurocrine Biosciences (NASDAQ:NBIX) is set to announce its Q313 earnings results on Tuesday, October 29th. Analysts expect Neurocrine Biosciences to post earnings of ($0.20) per share for the quarter.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 1.60% on Monday, hitting $10.48. 205,473 shares of the company’s stock traded hands. Neurocrine Biosciences has a 1-year low of $6.72 and a 1-year high of $15.33. The stock’s 50-day moving average is $14.40 and its 200-day moving average is $12.86. The company’s market cap is $702.8 million.
NBIX has been the subject of a number of recent research reports. Analysts at Roth Capital cut their price target on shares of Neurocrine Biosciences from $18.00 to $16.00 in a research note to investors on Tuesday, September 10th. They now have a “buy” rating on the stock. On the ratings front, analysts at Leerink Swann reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note to investors on Tuesday, September 10th. Finally, analysts at Cowen and Company cut their price target on shares of Neurocrine Biosciences from $20.00 to $19.00 in a research note to investors on Tuesday, September 10th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $16.19.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.